NAD Precursors: How to Select the Right Agent Within the Class

Are the four NAD+ precursors interchangeable?

They are grouped as one class because all of them feed NAD+ synthesis. NAD+ itself is a coenzyme in cellular energy metabolism and the substrate for sirtuins and PARP enzymes [10]. The human data behind them are not equivalent, though. NMN and NR have randomized trials that measured blood NAD+ before and after dosing [1][2]. Nicotinic acid's outcome evidence comes from its use as a lipid drug at gram doses [5].

NMN: what the human trials measured

Several randomized trials tested NMN at 250 mg/day. In one, 30 healthy adults took 250 mg/day or placebo for 12 weeks (15 per group); whole-blood NAD+ increased significantly and no adverse effects or laboratory abnormalities appeared [1]. In older men given 250 mg/day for 6 or 12 weeks, blood NAD+ and its metabolites rose, with nominally significant improvements in gait speed and left grip that the authors said needed confirmation in larger studies; body composition did not change [15]. A 12-week trial of 108 older Japanese adults assessed sleep, fatigue and physical performance; every group, including placebo, improved on the five-times sit-to-stand test, with the largest effect sizes in the group taking NMN in the afternoon (d=0.72 for sit-to-stand, d=0.64 for drowsiness) [9].

The dose-ranging trial gives the clearest picture of daily dosing. Eighty healthy middle-aged adults took placebo or NMN 300, 600 or 900 mg/day for 60 days. Blood NAD rose in every NMN group compared with placebo and baseline (all p ≤ 0.001) and was highest at 600 and 900 mg. Six-minute walk distance was greater than placebo in all NMN groups, and no safety issues were reported [7].

The highest daily dose tested for safety was 1,250 mg once daily for up to 4 weeks in 31 healthy adults aged 20-65, randomized and placebo-controlled: no severe adverse events and no changes beyond normal physiological variation in hematology, biochemistry, urine or body composition [11].

Physical-function results have been mixed. A 2025 systematic review and meta-analysis of randomized trials in older adults (mean age 60.9 to 83 years) found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed or five-times chair stand [3]. A second 2025 meta-analysis, 12 studies and 513 participants, found NMN raised blood NAD but most clinical outcomes, including fasting glucose, triglycerides and cholesterol, were not significantly different from control; risk of bias had some concerns in 7 studies and was high in 5 [4].

NR: what the human trials measured

In a randomized, placebo-controlled crossover trial in healthy middle-aged and older adults, NR was well tolerated and stimulated NAD+ metabolism [2]. Blood pressure changes were not significant; a post hoc subgroup with elevated baseline blood pressure showed a larger systolic difference, which the authors described as exploratory [2]. Mild events such as nausea, flushing, leg cramps and bruising occurred, with no serious events [2].

In a separate 21-day crossover trial, 12 men aged 70-80 took NR 1 g/day. Muscle NAD+ did not rise (210 vs 197 pmol/mg, p=0.22), while NAAD, a marker of NAD+ synthesis, doubled; mitochondrial respiration, grip strength, insulin sensitivity and muscle blood flow were unchanged, and circulating IL-6 and IL-5 were lower than at baseline [8].

A larger metabolic trial was also null: 40 sedentary obese men aged 40-70 took NR 1,000 mg twice daily (2,000 mg/day) or placebo for 12 weeks, with no improvement in insulin sensitivity by clamp, energy expenditure, lipolysis or body composition, and no serious adverse events [16].

Higher doses have been tested in Parkinson's disease. In a 20-person trial (10 on NR), NR 1,500 mg twice daily (3,000 mg/day) for 4 weeks produced no moderate or severe adverse events, raised blood NAD+ up to 5-fold, and caused a slight initial rise in serum homocysteine [12]. In a separate phase I trial, 30 newly diagnosed untreated patients took NR 1,000 mg/day or placebo for 30 days; it was well tolerated, brain NAD rose but variably, and the clinical improvement signal was mild [17]. In the high-dose trial, the apparent improvement in MDS-UPDRS scores was associated with a shorter interval since the last levodopa dose, so that result is confounded [12].

Which precursor has data on insulin sensitivity?

The most-cited NMN metabolic trial enrolled postmenopausal women with prediabetes who were overweight or obese, randomized, placebo-controlled and double-blind over 10 weeks. Insulin-stimulated glucose disposal measured by clamp rose after NMN and did not change after placebo, and muscle insulin signalling (AKT and mTOR phosphorylation) increased [10]. The paper drew a published comment and response disputing its analysis [10]. On the NR side, 2,000 mg/day for 12 weeks did not improve insulin sensitivity in obese men [16].

What about niacin and nicotinamide?

Nicotinic acid has a long history as a lipid drug: at gram doses it lowers VLDL, LDL and Lp(a) and raises HDL more than any other drug, according to a 2005 review [5]. That evidence concerns lipids at gram doses, not NAD+ repletion. Nicotinamide is the amide form of niacin; in laboratory studies it inhibits Sir2 enzymes noncompetitively [14]. That is a laboratory observation, not a human dose-response finding.

What is the regulatory status of each product?

Neither NMN nor NR is an FDA-approved drug, and no NAD+ precursor is approved to treat aging or any disease [6]. FDA now treats NMN as eligible for sale as a dietary supplement, subject to new-dietary-ingredient requirements [6]. That follows a reversal: trade press reported that in 2022 FDA told two ingredient makers that NMN could not be marketed as a dietary supplement under the drug-exclusion clause, a citizen petition followed in March 2023 [18], and on 2025-09-29 FDA posted a response concluding that NMN is not excluded from the supplement definition [6]. NMN is not banned.

For NR, FDA answered a GRAS notice from ChromaDex (GRN 000635) with a 'no questions at this time' letter dated 2016-08-03 and stated that it had not made its own GRAS determination [19].

Injectable or IV NAD+ is a compounded product rather than an FDA-approved drug [13].

Tolerability and what is not known

The trial record for NMN and NR is short and small. Long-term safety data beyond about 12 weeks are lacking, and the trials enrolled 12 to 140 people [20]. Pregnancy, breastfeeding, children, and people with cancer or kidney or liver disease were not studied, so safety in those groups is unknown [20]. Chronic NAD+ boosting has been raised as a theoretical cancer concern, but no human data were identified [20]. At the doses tested, NMN from 250 to 1,250 mg/day produced no safety issues in the trials above [1][7][11], and NR at 1,000 to 3,000 mg/day produced mild events such as nausea, flushing, leg cramps and bruising but no serious ones [2][12][16].

Can a NAD+ precursor be taken with prescription drugs?

A 2023 review identified no human drug-interaction studies of NMN or NR covering CYP enzymes, drug transporters or pharmacodynamic interactions [20]. Neither safety with, nor an interaction with, a specific prescription drug has been established. In the high-dose NR trial in Parkinson's disease, the apparent clinical improvement tracked with a shorter interval since the last levodopa dose, which confounds that result [12].